IVHEM 2019 REQUEST FOR SUPPORT INTERNATIONAL VIRAL HEPATITIS ELIMINATION MEETING.

Size: px

Start display at page:

Download "IVHEM 2019 REQUEST FOR SUPPORT INTERNATIONAL VIRAL HEPATITIS ELIMINATION MEETING."

Bethany Francis
5 years ago
Views:

1 INTERNATIONAL VIRAL HEPATITIS ELIMINATION MEETING 2019 AMSTERDAM, THE NETHERLANDS NOVEMBER 2019 REQUEST FOR SUPPORT

2 OVERVIEW INTRODUCTION TO The 5th edition of was organized on 6-7 December 2018 in Amsterdam, the Netherlands. It attracted 99 participants from 34 countries. This high-profile meeting brought together crucial stakeholders to share their experiences, research and views on how to eliminate viral hepatitis by The program featured plenary lectures, abstract and poster presentations, along with discussion & debates; providing a unique setting for knowledge exchange. BASIC FACTS AND FIGURES 8 abstract talks 37 poster presentations 94% Intend to change their daily practice after attending reaches a wide variety of leading experts with different backgrounds 35% Returning participants 100% Indicated there is a need for a focused program on elimination AREAS OF EXPERTISE EMPLOYER HIV (18%) Hepatology (10%) 41% HBV Hepatitis (39%) 30% HCV Government agency (9%) Other (11%) Research institute (9%) (University) Hospital (25%) 11% HIV University (11%) NGO (23%) Other (33%) Industry (12%) International viral hepatitis elimination meeting - meeting prospectus

INTRODUCTION Hepatitis B and C affect more than 320 million people globally. It is the primary cause of liver cancer and the second leading cause of cancer deaths in the world.

An estimated 71 million people (globally, 1%) are chronically infected with the Hepatitis C virus (HCV), resulting in nearly 399 000 deaths annually.

Listen to our key experts talk about Key issues to be addressed are how to translate research outcomes into public health policy and practice to meet the 2030 elimination targets.

number of people accessing testing and treatment.

3 INTRODUCTION Hepatitis B and C affect more than 320 million people globally. It is the primary cause of liver cancer and the second leading cause of cancer deaths in the world. Around 257 million people are chronically infected with HBV, and approximately 2 people die each minute from Hepatitis B. An estimated 71 million people (globally, 1%) are chronically infected with the Hepatitis C virus (HCV), resulting in nearly deaths annually. Despite these facts, only 20% of HCV-infected people are diagnosed and only a small portion of diagnosed patients enter the cascade of care to receive treatment. Listen to our key experts talk about Key issues to be addressed are how to translate research outcomes into public health policy and practice to meet the 2030 elimination targets. During this meeting, experts in viral hepatitis from around the globe will examine current evidence on how to implement programs that improve the prevention of viral hepatitis, and increase the number of people accessing testing and treatment. Margaret Hellard Burnet Institute Meeting Chair 2018 Involving community organizations, researchers, public health practitioners and clinicians, the program includes practical examples of innovative intervention studies, country elimination programs and novel funding mechanisms for testing and treatment, all focusing on meeting the 2030 targets. Jordan Feld Toronto Center for Liver Disease Meeting Chair 2018 Michael Ninburg World Hepatitis Alliance Program Committee Jeffrey Lazarus ISGlobal Hospital Clinic, University of Barcelona Program Committee International viral hepatitis elimination meeting - meeting prospectus

COMMITTEES WORLD S LEADING EXPERTS proudly collaborates with a large number of

By collaborating with a global network of key experts from various backgrounds we can

ORGANIZING COMMITTEE The members of the Organizing Committee (OC) are carefully selected

They come together on a frequent basis to develop the scientific program tailored to the

Furthermore, they identify clinical cases and research projects within their

They actively participate as session chairs and join the Q&A sessions, discussions and

Charles Boucher MD, PhD Erasmus Medical Center, Rotterdam, the Netherlands Jordan Feld

FAFPHM, PhD Burnet Institute, Melbourne, Australia Manal El-Sayed MD, PhD Ain Shams

4 COMMITTEES WORLD S LEADING EXPERTS proudly collaborates with a large number of international experts in the field of viral hepatitis. By collaborating with a global network of key experts from various backgrounds we can ensure the most relevant and state-of-the-art program. ORGANIZING COMMITTEE The members of the Organizing Committee (OC) are carefully selected experts and inspirational leaders in their respective fields. They come together on a frequent basis to develop the scientific program tailored to the needs of Healthcare professionals in the field. Furthermore, they identify clinical cases and research projects within their organizations/ network and review and select abstracts. They actively participate as session chairs and join the Q&A sessions, discussions and debates during the meeting. Charles Boucher MD, PhD Erasmus Medical Center, Rotterdam, the Netherlands Jordan Feld MD, Toronto Centre for Liver Disease, Toronto, Canada Margeret Hellard MBBS, FRACP, FAFPHM, PhD Burnet Institute, Melbourne, Australia Manal El-Sayed MD, PhD Ain Shams University, Cairo, Egypt Angelos Hatzakis MD, PhD Athens University Medical School, Athens, Greece 'Funmi Lesi FWACP, FMCP University of Lagos, Lagos, Nigeria Michael Ninburg Hepatitis Education Project, USA John Ward MD U.S. Centers of Disease Control and Prevention, USA International viral hepatitis elimination meeting - meeting prospectus

5 COMMITTEES SCIENTIFIC COMMITTEE The members of the Scientific Committee (SC) are hand-picked by the OC and the conference secretariat based on their significant contributions and commitment to the field. They assist the OC by providing them with topic and speaker suggestions. In addition, members of the SC participate in reviewing submitted abstracts, and play an active role during the workshop. Maia Butsashvili - Director, Health Research Union, Tblisi, Georgia Jude Byrne - Senior Project Officer, Australian Injecting & Illicit Drug Users League (AIVL), Canberra, Australia Vladimir Chulanov -Head of Reference Center for Viral Hepatitis, Moscow, Russia Andrea Cox - Professor of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA Khin Pyone Kyi - President of Board of Directors, Myanmar Liver Foundation, Rangoon, Myanmar Jeffrey Lazarus - Affiliated Professor, CHIP, Copenhagen, Denmark Liudmyla Maistat - Policy and Advocacy Manager, Medicines Patent Pool, Geneva, Switzerland Francesco Marinucci - Head HIV/HCV Unit, FIND, Geneva, Switzerland Shruti Mehta - Deputy Chair, Department of Epidemiology, Johns Hopkins School of Medicine, Baltimore, MD, USA Jean-Michel Pawlotsky - Professor of Medicine, Hôpital Henri Mondor, Paris, France Huma Qureshi - Pakistan Medical Research Council, Islamabad, Pakistan Homie Razavi - Managing Director, Center for Disease Analysis (CDA), Louisville, CO, USA Tatjana Reic - President, European Liver Patients Association, Brussels, Belgium Marcelo Silva - Head of Hepatology and Liver Transplant Unit, Austral University Hospital, Buenos Aires, Argentina International viral hepatitis elimination meeting - meeting prospectus

6 NEEDS ASSESSMENT NEEDS ASSESSMENT The field of viral hepatitis treatment is undergoing major changes and is on the verge of a paradigm shift. There are great hopes for the eliminatin of viral hepatitis. Many new treatment options are becoming available through the introduction of Direct Acting Antivirals (DAAs) and are providing great hopes for decreasing the burden of disease and simplifying the treatment of viral hepatitis. The International Viral Hepatitis Elimination Meeting () is a global forum for the exchange of practical experiences in the translation of diagnostic and therapeutic advances into broad applications that accelerate progress toward elimination of viral hepatitis as a public health threat. The program features outstanding international experts that address strategies regarding testing & screening, care & cure, prevention, and innovative models to finance elimination strategies. Meeting objectives The objectives of this meeting are to: Provide a forum for knowledge exchange and discussion of practical experiences of advances in diagnostics and clinical management of viral hepatitis. Provide a toolbox for practical application of research & development, for evidence based policy making Facilitate cross-disciplinary discussion on barriers and challenges to achieve the elimination of viral hepatitis Learning objectives TARGET AUDIENCE Healthcare professionals, including but not limited to clinicians, researchers, policy makers, virologists, pharmacologists, industry representatives, and those looking beyond the individual patient and who would like to be involved in the elimination of viral hepatitis. ESTIMATED NUMBER OF PATICIPANTS participants After attending this program participants will be able to: Identify the roadblocks and the challenges in implementing viral hepatitis elimination strategies Recognize the needs from a public health perspective and respond to these needs by reshaping their policy making approaches Further develop new or already existing foundations for political commitment, national planning and program improements. Translate the latest research and technologies into clinical policy and practice for delivering adequate continuum of hepatitis services International viral hepatitis elimination meeting - meeting prospectus

7 PROGRAM PROGRAM DESCRIPTION This 1.5 day meeting consists of invited lectures, roundtable discussions, abstract-driven presentations and poster-viewing sessions. The program mainly involves speakers with hands-on experience in eliminating viral hepatitis in a certain setting. As a result, is able to provide a toolbox for practical experiences of advances in diagnostics and clinical management of viral hepatitis. Previous meeting topics Monitoring: Finding the missing millions HBV Monitoring: Finding the missing millions HCV Linkage to Care (both in HBV and HCV) - How can we keep patients in the care continuum? Surveillance (surveillance in countries that are eliminating, what do they do with resistant cases?) Public health (local communities versus global health, public s awareness of public health challenges, health systems) FORMAT This 1.5 day meeting consists of invited lectures, roundtable discussions and abstract-driven presentation. In order to ensure an interactive workshop setting, much time is allocated to discussion International viral hepatitis elimination meeting - meeting prospectus

8 ENDURING MATERIALS INFECTIOUS DISEASES ONLINE Enduring information presented at the conference will be freely accessible and widely disseminated to reach thousands of virtual participants beyond the walls of the conference center. Infectious Diseases Online is a premier online platform offering scientific materials in special topical areas and proceedings of conferences. All the content on Infectious Diseases Online is organized by workshop and date, making it easy to find. Visitors of the website will have full access to: Abstract Books Meeting Reports Workshop Presentations Webcasts International viral hepatitis elimination meeting - meeting prospectus

9 ASSESSMENT LEARNING ASSESSMENT METHOD To assess the meeting, Virology Education provides each delegate with a detailed feedback form to assess the speakers, whether or not the meeting objectives were met, their intent to change, the rationale behind their motivation to attend, the general logistics of the meeting, and more. All the questions are then fully analyzed and a comprehensive report is created and shared with the committee members. These reports help us to better understand our delegates needs and how to improve the meeting in the future. Accreditation We aim to submit an application to the EACCME for CME accreditation of this event. For a maximum response rate, we invite the chairs of each session to encourage the participants to take a few minutes and complete the feedback forms. We are also introducing a web-based application to allow participants access to the feedback forms electronically. Conference participation grants The conference participation grants (CPG) provide healthcare professionals with the opportunity to attend a conference they would otherwise be unable to attend due to financial restrictions. All applications include a CV, a motivation letter, and potentially an abstract (requirements vary depending on the workshop). These are submitted via an independent CPG portal and are evaluated against the assessment criteria using a robust, impartial and independent peer review process. This process will ensure that the most qualified candidates will receive CPGs. The grants are supported by the financial contributions allocated by the sponsor, who has no control, influence, or involvement in the selection process of the CPG candidates whatsoever. Priority is given to applicants who have actively participated in original research or scientific work that is being presented at the meeting and/or those who will profit most from participating in order to improve their daily clinical management. These grants help defray costs for registration, travel and accommodation for delegates and foster their ability to form valuable professional networks and develop vital collaborations. Conference participation grant applications will be solicited, selected and awarded by an expert Grant Review Committee. Please note that the TITANIUM, PLATINUM and GOLD support levels will reduce the costs for conference participation grants International viral hepatitis elimination meeting - meeting prospectus

10 ACKNOWLEDGEMENTS MEETING PARTNERS HAS PREVIOUSLY BEEN SPONSORED BY International viral hepatitis elimination meeting - meeting prospectus

11 SPONSORSHIP SPONSOR BENEFITS As a sponsor of, you will have the unique opportunity to connect with clinicians and researchers from academia, research institutes and governments. Engage with potential collaborators and experts and discuss the latest advancements and information in the field of viral hepatitis. Sponsoring this program will give you the following benefits: Visibility Prominent placement of your logo on conference materials (online and offline) Pre-event marketing and branding through: - Banners posted on the homepage of the website - Traffic generation to your website via the conference website - Your logo placed on monthly newsletters which are delivered to thousands of opt-in subscribers - Electronic advertising posted on several calendars linked to the event website Contribution to the program A chance to organize satellite symposia Participate in discussions Commercial benefits Exhibition opportunities Promotion option to display marketing materials such as pamphlets, flyers, postcards and other materials on the marketing table (subject to approval) Privileges Your contribution entitles you to the following privileges: Exhibition space Symposia inclusion Complimentary registrations to the event to increase your networking opportunities Other benefits described under various sponsorship levels International viral hepatitis elimination meeting - meeting prospectus

ABOUT US VIROLOGY EDUCATION With over 20 years of experience, Virology Education is a leading provider of innovative scientific and educational programs worldwide.

liver disease, and more. Our activities include the initiation and organization of real-time and online platforms for international exchange, knowledge-sharing and education for medical professionals.

12 ABOUT US VIROLOGY EDUCATION With over 20 years of experience, Virology Education is a leading provider of innovative scientific and educational programs worldwide. Our programs provide excellent platforms for scientific exchange, education and knowledge-sharing tailored to the needs of healthcare professionals in the fields of infectious diseases, pharmacology, liver disease, and more. Our activities include the initiation and organization of real-time and online platforms for international exchange, knowledge-sharing and education for medical professionals. We have developed long-standing collaborations with world-leading experts and work together with other important stakeholders to achieve the greatest impact for our programs and to provide top quality scientific content. Our programs range from international abstract-driven workshops to small and large scale educational series, masterclasses, advisory boards, expert rounds, satellite symposia, and more. Biltstraat BJ Utrecht The Netherlands info@virology-education.com Karin Siebelt Project Manager Karin@vironet.com More than 50 programs are planned for 2018 in more than 30 different cities around the globe! Wilco Keulen, PhD Senior Scientist wilco@vironet.com OUR IMPACT IN programs 4,187 participants 2,277 accepted abstracts 59% returning participants 28,000+ opt in subscribers

INTERNATIONAL MASTERCLASS ON LIVER DISEASE IN HIV VILNIUS, LITHUANIA 18 SEPTEMBER 2019 (TBC) REQUEST FOR SUPPORT.

INTERNATIONAL MASTERCLASS ON LIVER DISEASE IN HIV VILNIUS, LITHUANIA 18 SEPTEMBER 2019 (TBC) REQUEST FOR SUPPORT INTRODUCTION Liver disease in the setting of HIV is increasingly presenting a major concern